Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy

Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K (2020)


Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 11

Pages Range: 6081-6089

Journal Issue: 20

DOI: 10.7150/jca.47698

Abstract

Background: While subtyping of the majority of malignant chromophobe renal cell carcinoma (cRCC) and benign renal oncocytoma (rO) is possible on morphology alone, additional histochemical, immunohistochemical or molecular investigations are required in a subset of cases. As currently used histochemical and immunohistological stains as well as genetic aberrations show considerable overlap in both tumors, additional techniques are required for differential diagnostics. Mass spectrometry imaging (MSI) combining the detection of multiple peptides with information about their localization in tissue may be a suitable technology to overcome this diagnostic challenge.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Kriegsmann, M., Casadonte, R., Maurer, N., Stoehr, C., Erlmeier, F., Moch, H.,... Kriegsmann, K. (2020). Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 11(20), 6081-6089. https://dx.doi.org/10.7150/jca.47698

MLA:

Kriegsmann, Mark, et al. "Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy." Journal of Cancer 11.20 (2020): 6081-6089.

BibTeX: Download